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Abstract 
Rat mast cell protease 1(RMCP-1) is a chymotrypsin-like s rine protease specifically expressed by connective tissue-type mast cells. The enzyme 
is stored in the secretory granules in a macromolecular complex with heparin proteoglycan. In the present investigation it was shown that RMCP-1 
is inhibited by vitronectin (VN), an RGD-containing adhesive glycoprotein with heparin-binding properties. RMCP-1 that had been separated from 
heparin proteoglycan was less susceptible to inhibition than RMCP-1 present in complex with heparin proteoglycan. Pre-incubation of VN with 
purified heparin partially blocked the RMCP-1 inhibiting activity of VN. Plasma VN had negligible RMCP-l-inhibiting activity. However, heat 
treatment of plasma VN, which is known to expose the heparin-binding domain, induced RMCP-1-inhibiting activity. Affinity chromatography on
immobilized VN showed that RMCP- 1 bound with high affinity to VN. The binding of RMCP- 1 to VN was not heparin-dependent si ce free RMCP- 1 
bound with equal affinity to the immobilized VN as RMCP-1 present in complex with heparin. The inhibition of RMCP-1 by VN was shown to 
be reversible. 
Key words: Vitronectin; Mast cell; Serine protease; Chymase; Heparin; Heparin-binding site 
1. Introduction 
Mast ceils synthesize various inflammatory mediators, 
including histamine, chemotactic factors, proteoglycans, 
carboxypeptidases and serine proteases, that are stored 
in the secretory granules and are exocytosed following 
mast cell activation [1]. The mast cell secretory granule 
serine proteases constitute a family of related enzymes, 
including proteases of trypsin- (tryptases) and chymot- 
rypsin-like (chymases) ubstrate specificities [2-6]. Dur- 
ing the purification of rat mast cell protease 1 (RMCP-1), 
a chymotrypsin-like serine protease with thrombin-inac- 
tivating properties expressed by rat peritoneal mast ceils, 
we observed that the protease is recovered from the ceils 
as a macromolecular complex with heparin proteogly- 
cans [7,8]. Heparin is a sulfated glycosaminoglycan 
displaying a high anionic charge density [9]. In the pro- 
teoglycan form, the heparin chains are covalently at- 
tached to a protein core. When RMCP-1 was separated 
from the heparin proteoglycan, the protease lost its abil- 
ity to inactivate thrombin. Since RMCP-1 regained its 
thrombin-inactivating properties after reconstitution 
with heparin, we proposed that the association with hep- 
arin was important for the proteolytic activity of the 
enzyme. Polybrene, a polycationic heparin antagonist, 
was shown to inhibit RMCP-1 activity, further support- 
ing the involvement ofthe heparin moiety of the RMCP- 
1/heparin complex in the proteolytic activity of RMCP-1 
[7]. 
Vitronectin (VN) is a multifunctional dhesive glyco- 
*Corresponding author. Fax (46) (18) 174975. 
Abbreviations: RMCP, rat mast cell protease; VN, vitronectin; PBS, 
phosphate-buffered saline. 
protein containing the RGD-sequence motif, implicated 
in the process of cellular adhesion mediated by integrins 
[10,11]. In addition, VN contains binding sites for vari- 
ous ligands uch as heparin [10], collagen [12], plasmino- 
gen activator inhibitor type 1 [13] complement compo- 
nents [14] and thrombin/antithrombin complexes [15], as 
well as an acidic domain [16]. Some of these sites appear 
to be cryptic in the plasma form of VN but become 
exposed after unfolding of the molecule following treat- 
ment of VN by denaturing agents [17-19] or possibly by 
various physiological inducers [20,21] When the heparin- 
binding domain is exposed, VN gains potent heparin- 
neutralizing activity [22] and these findings encouraged 
us to assess whether VN, by interacting with the heparin 
moiety of the RMCP-1/heparin proteoglycan complex, 
had the capacity to inhibit the proteolytic activity of 
RMCP-1. In the present work we indeed show that VN 
inhibits RMCP-1 activity. It is, to our knowledge, the 
first report where protease inhibitory activity is attri- 
buted to VN. 
2. Materials and methods 
The chromogenic peptide substrate S-2586 was from Chromogenix 
(M61ndal, Sweden). Bovine chymotrypsin was a generous gift from I. 
Bj6rk (Dept. Veterinary Medical Chemistry, Uppsala, Sweden). Unla- 
beled and [3H]NAc-labeled pig mucosal heparins were kindly donated 
by Ulf Lindahl (Dept. Medical and Physiological Chemistry, Uppsala, 
Sweden). CNBr-activated Sepharose 4B and heparin-Sepharose w re 
purchased from Pharmacia (Uppsala, Sweden). Purified VN (~ 2 mg) was 
coupled to ~2 ml of CNBr-activated Sepharose 4B according to the 
procedure described by the manufacturer. 
Plasma VN, purified according to the method of Dahlb~ick and 
Podack [23], was a gift from D.E Mosher (Dept. Medicine, University 
of Wisconsin at Madison, USA). The method for purification utilizes 
mild chromatographic steps that do not significantly alter the native 
conformation of VN. Unfolded VN was purified according to the 
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method of Yatohgo et al. [24]. This method involves treatment of 
plasma VN with urea followed by affinity chromatography on heparin- 
Sepharose. 
RMCP-1 present as a macromolecular complex with heparin pro- 
teoglycan was purified from rat peritoneal mast cells by anion-exchange 
chromatography on DEAE-Sephacel [7]. Free RMCP-1 was obtained 
after further purification on a Superdex 75 column as described [7]. 
RMCP-1 activities were measured in 96-well microtiter plates. 
RMCP-1 was diluted with PBS, 0.1% Triton X-100 to a final volume 
of 200 pl. Enzyme activity was detected after addition of 20 pl of the 
chromogenic chymotrypsin substrate S-2586 (4 mM in H20), and mon- 
itoring of the absorbance at405 nm with a Titertek Multiscan spectro- 
photometer (Flow Laboratories). In the inhibition studies, RMCP-1 
was pre-incubated for 5 min with VN before the addition of S-2586. 
Calculations of Ki values for the inhibition of RMCP-1 by VN were 
carried out as described [25]. 
Affinity chromatography of RMCP-1 on VN--Sepharose was per- 
formed on a column (~0.6 ml) equilibrated with PBS, 0.1% Triton 
X-100. Samples of RMCP-I, RMCP-1/heparin complexes or 3H-la- 
beled heparin were applied to the column, followed by washing of the 
column with 2 x 1 ml of equilibrating buffer. The column was then 
eluted stepwise with PBS, 0.1% Triton X-100 containing 0.3, 0.5, 1, 2 
and 3 M NaC1, respectively (2× 1 ml of each buffer). The eluted frac- 
tions were subsequently analyzed for RMCP-1 activity or 3H radioac- 
tivity. 
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Fig. 2. Blocking of RMCP-1-inhibiting activity of VN by heparin. VN 
at the concentrations indicated was pre-incubated with 5/zg/ml (e), 20 
/tg/ml (D) or 100 pg/ml ( l)  of heparin (standard pig mucosal heparin), 
or without added heparin (o). After 15 min, RMCP-1/heparin pro- 
teoglycan complex (~ 0.2/gg of RMCP- l/ml) was added to the incubation 
mixtures, and, after an additional 5min, residual RMCP-1 activity was 
determined with the chromogenic substrate S-2586. 
3. R ~  
RMCP-1 has previously been shown to be recovered 
in a macromolecular complex with heparin proteoglycan 
[7]. Incubation of complex-bound RMCP-1 with un- 
folded VN resulted in inhibition of the protease, as meas- 
ured by the cleavage of the chromogenic chymotrypsin 
substrate S-2586 (Fig. 1). VN at similar concentrations 
also inhibited the ability of the complex-bound RMCP-1 
to inactivate thrombin (not shown). Free RMCP-1, sep- 
arated from the heparin proteoglycan by gel-filtration in 
high salt (see [7]), was also inhibited by VN. However, 
higher VN concentrations were required for inhibition of 
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Fig. 1. Inhibition of RMCP-I and chymotrypsin by VN. Free RMCP-1 
(-0.2 pg/ml; o), RMCP-1/heparin proteoglycan complex (-0.2/gg of 
RMCP- l/ml; e) or chymotrypsin (~ 0.2pg/ml; m) were pre-incubated for 
5 rain with VN at the concentrations indicated. Subsequently, residual 
protease activity was determined after addition of the chromogenic 
substrate S-2586. The solid lines are the fitted curves, generated using 
the best estimates calculated by non-linear regression analysis. 
the free protease. Purified chymotrypsin was not inhib- 
ited by VN (Fig. 1). Calculations based on the data 
shown in Fig. 1 showed that the Ki value for the inhibi- 
tion of complex-bound RMCP-1 was 3.6 + 1.2 nM, 
whereas the Ki for the inhibition of free RMCP-1 was 
2 + 7 nM, thus indicating that the inhibition of complex- 
bound RMCP-1 by VN is ~ 7-fold more effective than the 
inhibition of free RMCP-1. The calculations of Ki values 
are based on the assumption that VN is present in the 
monomeric form. However, VN has a tendency to mul- 
timerize [18], and therefore the Ki values hould be taken 
as approximate. 
The finding that RMCP-1, complex-bound to heparin, 
is more readily inhibited by VN than free RMCP-1 sug- 
gests the involvement of the RMCP-l-associated heparin 
proteoglycan i the inhibition mechanism. As VN con- 
tains a heparin-binding domain it appeared likely that 
VN interacts with the heparin moiety of the RMCP-1/ 
heparin complex. This possibility was tested in experi- 
ments where VN was pre-incubated with standard pig 
mucosal heparin before addition to the RMCP-1/heparin 
proteoglycan complex. The obtained results howed that 
exogeneous heparin partially blocked the protease-inhib- 
itory activity of VN in a dose-dependent manner (Fig. 2). 
The above findings indicated that the heparin-binding 
domain of VN may participate in the inhibition of 
RMCP-1. Plasma VN represents a form of the molecule 
where the heparin-binding site is buried. However, vari- 
ous treatments of VN, such as treatment with 8 M urea 
or heat treatment of the molecule, are known to expose 
the heparin-binding domain. To further study the inhibi- 
tion mechanism, the RMCP-l-inhibiting activities of 
plasma VN and unfolded VN were compared. Plasma 
VN was shown to be a poor inhibitor of RMCP-I 
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Fig. 3. Inhibition of RMCP-1 by plasma VN. RMCP-1/heparin pro- 
teoglycan complex (-0.2/ag of RMCP-l/ml) was incubated with plasma 
VN (o) or plasma VN that had been heated at 95°C for 2 min (o). After 
5 min, residual RMCP-1 activity was determined after addition of the 
chromogenic substrate S-2586. 
RMCP-1 was subjected to affinity chromatography on
immobilized VN (VN-Sepharose). RMCP-1 present in 
the macromolecular complex with heparin proteoglycan 
bound strongly to the affinity matrix. Stepwise lution of 
the column showed that most of the RMCP-1 activity 
was eluted at 1-2 M NaC1 (Fig. 5A). Free RMCP-1, 
separated from the heparin proteoglycan displayed simi- 
lar affinity for the immobilized VN as complex-bound 
RMCP-1 (Fig. 5A). Affinity chromatography of 3H-la- 
beled heparin chains on the VN-Sepharose column 
showed that the radiolabeled heparin bound to the col- 
umn and eluted at ~0.5 M NaC1. When a mixture of 
3H-labeled heparin and RMCP-1 (separated from the 
heparin proteoglycan) was applied to the immobilized 
VN, the radiolabeled heparin eluted at ~0.5 M NaCI, 
whereas the RMCP-1 activity showed a similar elution 
profile as the free RMCP-1 (Fig. 5B). 
(Fig. 3). In contrast, plasma VN that had been heated at 
95°C for 2 min inhibited RMCP-1 effectively (Fig. 3). 
Experiments were conducted to assess whether the in- 
hibition of RMCP-1 by VN was reversible. RMCP-1/ 
heparin proteoglycan complex was incubated at 0.15 M 
NaC1 with VN at a concentration sufficient o achieve 
essentially total inhibition of the protease (Fig. 4A). Sub- 
sequently, NaC1 was added both to control incubations 
of RMCP-1/heparin proteoglycan and to incubations of 
RMCP-1/heparin proteoglycan containing VN, yielding 
final NaC1 concentrations of 0.3 M and 0.5 M, respec- 
tively (Fig. 4B). The higher salt concentrations resulted 
in a slight inhibition of the RMCP-1 present in the con- 
trol incubations. Moreover, at 0.3 M NaCI, partial re- 
covery of RMCP-1 activity from incubations containing 
RMCP-1/heparin proteoglycans and VN was observed. 
At 0.5 M NaC1, total recovery of the RMCP-1 activity 
previously inhibited by VN was obtained, demonstrating 
that the inhibition of RMCP-1 by VN is reversible (Fig. 
4B). 
To further study the interaction of RMCP-1 with V'N, 
4. Discussion 
RMCP-1 is a highly basic protein with a net positive 
charge of + 18 [2]. The high positive charge displayed by 
the protease suggests the potential of interaction with 
various acidic molecules. Indeed, RMCP-1 is stored in 
the granules in a macromolecular complex with heparin 
proteoglycan [7,26], and is released from the mast cells 
bound to the heparin proteoglycan [27]. The association 
of RMCP-1 with heparin appears to influence the activ- 
ity of the enzyme. Yurt and Austen [26] and Sayama et 
al. [28] have reported that heparin reduces the activity of 
mast cell chymase. In contrast, Gervasoni et al. [29] have 
shown that interaction of the mast cell chymase with 
heparin is necessary for the degradation of anaphyla- 
toxin C3a. Further, we have recently shown that the 
association of RMCP-1 [7,8] and also mouse mast cell 
chymase [30] with heparin is required for the inactivation 
of thrombin. As thrombin is known to interact with hep- 
arin, we proposed a mechanism where thrombin, by 
binding to the RMCP-l-associated heparin proteogly- 
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Fig. 4. Reversibility of the inhibition of RMCP-1 by VN. (A) RMCP-1/heparin proteoglycan complex (-0.2 pg of RMCP-1/ml) was incubated for 
5 min in the absence (open bar) or presence (hatched bar) of 2//g of VN, followed by determination f residual RMCP-I activity with the chromogenic 
substrate S-2586. (B) R MCP-1/heparin proteoglycan complex (~ 0.2 pg of RMCP-l/ml) was incubated for 5 min in the absence (open bars) or presence 
(hatched bars) of 2 pg of VN. After 5 rain, NaC1 from a stock solution containing 2 M NaC1 was added to the incubation mixtures, yielding final 
NaCI concentrations of 0.3 M and 0.5 M, respectively. RMCP-1 activity was determined after 5 min. 
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Fig. 5, Affinity chromatography on VN-Sepharose. (A) Samples of 
RMCP-1/heparin proteoglycan complex (- 0.5pg ofRMCP-1; II) or free 
RMCP-I (-0.5/Jg; 0) were applied to a column of VN-Sepharose. The 
column was eluted with PBS,0.1% Triton X-100 supplemented with 
NaC1 at the concentrations i dicated. Eluted fractions were analyzed 
for RMCP- 1 activity. (B) A sample of RMCP- 1 (~ 0.5/zg) was mixed with 
[3H]heparin (4,000 dpm) and was applied to the VN-Sepharose. Eluted 
fractions were analyzed for RMCP-1 activity (e) or 3H radioactivity 
(r~). (A) Affinity chromatography of [3H]heparin (4,000 dpm) on VN- 
Sepharose. 
can, is brought in close contact with the chymase, 
thereby facilitating proteolysis. Furthermore, we found 
that Polybrene, a polycationic heparin antagonist, inhib- 
ited the inactivation of thrombin by RMCP-1, presuma- 
bly by binding to the heparin moiety of the RMCP-1/ 
heparin proteoglycan complex [7]. We therefore hypoth- 
esized that naturally occurring heparin antagonists may 
have RMCP-1-inhibiting activity. Indeed, in the present 
report we show that VN inhibits RMCP-1. The mecha- 
nism of inhibition seemed to involve the heparin-binding 
site of VN since free RMCP-1, separated from the hepa- 
fin proteoglycan, was less susceptible to inhibition by 
VN. This notion is further supported by the experiments 
where pre-incubation of VN with heparin partially 
blocked its ability to inhibit RMCP-1. 
It is important to note that it is the unfolded form of 
VN that exerts the RMCP-l-inhibiting activity, as well 
as several other reported activities associated with the 
protein. Plasma VN was shown to have very low RMCP- 
1-inhibiting activity, consistent with only a minor por- 
tion of the circulating VN molecules being present in the 
unfolded form [17,31]. However, heat treatment of the 
plasma VN, which is known to unfold the protein [18], 
induced RMCP-l-inhibiting activity. The unfolding of 
VN exposes the heparin-binding domain along with 
other cryptic domains, and it thus appears that the un- 
folding process is necessary to achieve the RMCP-1- 
inhibiting activity. The unfolding procedure can also 
occur by exposure to various physiological agents, e.g. 
heparin [32], antithrombin/thrombin complexes [20] and 
complement complexes [21]. Thus, it appears that many 
physiological functions of VN, particularly those involv- 
ing heparin-binding [18,19], can be modulated. 
Affinity chromatography on immobilized (unfolded) 
VN showed that RMCP-1 exhibits high affinity for VN. 
The binding to VN did not appear to be mediated by the 
heparin moiety of the RMCP-1/heparin proteoglycan 
complex since free RMCP-1 bound equally well to VN- 
Sepharose as RMCP-1 present in complex with heparin 
proteoglycan. In fact, free RMCP-1 showed higher affin- 
ity for VN than did purified heparin. As RMCP-1 carries 
a high net positive charge [2], interaction with a nega- 
tively charged omain of VN would explain the binding 
of RMCP-1 to VN. Such an acidic domain of VN is 
located in the N-terminal region of the molecule close to 
the RGD sequence [16], and it is thus possible that this 
area of VN has the ability to bind to positively charged 
regions of RMCP-1. Since our results indicate that also 
the heparin-binding domain of VN is involved in the 
inhibition of RMCP-1 (see above), it is thus possible that 
optimal inhibition of RMCP-1 requires interaction of 
both the heparin-binding domain of VN with the heparin 
moiety of the RMCP-1/heparin proteoglycan complex, 
and interaction of the acidic domain of VN directly with 
RMCP-1. It is worth noting that 1-2 M NaC1 was re- 
quired for dissociation of RMCP-1 from the VN-Sepha- 
rose whereas 0.5 M NaCI was sufficient both for the 
dissociation of heparin from the VN-Sepharose and for 
the reversal of the inhibition of RMCP-1 (present in 
complex with heparin) by VN. 
Due to the multidomain structure of VN the protein 
is thought o have a variety of biological functions. The 
RGD sequence mediates the integrin-dependent cellad- 
hesion to VN [11]. Moreover, the interaction of VN with 
heparin [18,19], thrombin/serpin complexes and plasmin- 
ogen activator inhibitor type 1 [33,34] indicates a role for 
VN in the regulation of hemostasis. There is also evi- 
dence for the participation of VN in the immune defence. 
Specific interactions between VN and bacteria have been 
observed [35] and it is thought hat VN plays a role in 
the initial adherence of bacteria to host cells. VN has also 
been shown to inhibit the complement system by interfer- 
ing with the assembly of the membrane attack complex 
[14]. The involvement of VN in the inflammatory re- 
sponse is further suggested by the immunohistochemical 
identification of VN at inflammatory sites [33,34,36,37]. 
The biological function of the mast cell chymases i un- 
certain. However, various reported activities for the pro- 
teases [29,30,3840] indicate that they are involved in 
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inflammatory reactions. Considering the vast amounts 
of RMCP-1 present in the mast cell granules [27], it 
appears likely that a regulatory mechanism capable of 
neutralizing RMCP- 1, released after mast cell activation, 
is important. The present report identifies VN as a po- 
tent inhibitor of RMCP-1. Since VN appears to be pres- 
ent at inflammatory sites, the inhibition of RMCP-1 by 
VN may thus be of physiological significance in the reg- 
ulation of the inflammatory response. 
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